Advanced Synthesis in Focus - November 2025
From AI-powered synthesis to dual-payload ADCs, this November edition is packed with insights to help you stay ahead. Discover how Lonza’s digital tools are transforming early-phase development, the latest news in ADCs world, and where you can meet our team in November.
Experts Corner
Discover how AI is transforming early-phase drug development—making synthesis faster, more cost-efficient, and less risky. In this webinar, Lonza experts share real-world case studies and demonstrate how predictive tools are helping teams identify more effective chemical routes and crystal forms. This webinar is perfect for small molecule innovators looking to accelerate progress to clinic. 🔗 Watch now
Lonza’s AI-enabled toolkit is transforming early-phase drug development. Learn how digital tools like AI-enabled route scouting, high-throughput experimentation, and Design2Optimize™ are helping teams reduce risk, avoid unnecessary costs, and accelerate timelines by watching our latest webinar. 🔗 Watch now.
News & Noteworthy
We’re thrilled to announce Synaffix’s new partnership with Qurient Therapeutics to develop a dual-payload ADC—combining two powerful payloads to target cancer more effectively. This collaboration leverages Synaffix’s exatecan linker-payload tech and Qurient’s CDK7 inhibitor, aiming to boost efficacy and overcome resistance in solid tumors. 🔗 Read full article.
For early-stage biotechs, antibody–drug conjugates (ADCs) are emerging as a high-impact opportunity. With improved safety profiles and smarter payload-linker designs, ADCs are gaining traction across pipelines and partnerships. This article examines why now is the ideal time for biotech innovators to scrutinize ADCs—and how the latest advancements are transforming the landscape. 🔗 Read the full article
We’re proud to have our team at this year’s World ADC US, where our experts are sharing insights on advancing ADC manufacturing and clinical development.
Dominik Zetschok will explore how rapid process screening can translate into clinical success. Valentina Gualato, PhD is talking about scaling ADC processes from lab to GMP. Anette Sommer will present on emerging clinical insights from our GlycoConnect® Technology.
It is an inspiring week of collaboration and innovation in the ADC space. If you are going to miss any of our sessions and would like access to the presentations, feel free to request them here 👉World ADC 2025 | Lonza
At Lonza, our commitment to SDG 12: Responsible Consumption and Production drives how we source and collaborate. Through our Responsible Sourcing program, we’re raising the bar on social, environmental, and governance standards across our supply chain.
What does this look like in practice?
- We expect suppliers to complete sustainability assessments or audits with strong results.
- We encourage science-based target setting to drive measurable impact.
- We collaborate through the Together for Sustainability initiative, supporting suppliers with training, events, and ESG capability development. 🔗 Read more here.
Upcoming Webinars
📅 Thursday, November 20, 2025 | 17:00 CET | 11:00 am EDT
Amorphous solid dispersions (ASDs) are a proven strategy for boosting bioavailability of poorly soluble drugs—and hot melt extrusion (HME) is emerging as a scalable, cost-effective solution. In this webinar, Lonza experts Rick Falk and Ryan Teller will share insights from lab and pilot-scale trials using griseofulvin as a model compound. You’ll learn how key process variables like melt temperature, residence time, and shear rate impact ASD performance—and how to manage them during scale-up. 👉 Register here: Extrusion-Based ASD Scale-Up: Ensuring Performance Through Process Understanding.
📅 Thursday, December 4, 2025 | 16:00 CET | 10:00 am EDT
Discover how electrochemistry is reshaping synthetic chemistry—offering scalable, sustainable, and metal-free alternatives to traditional oxidative processes. Join Lonza’s Simon Wagschal and Dominique Roberge as they present recent advances in electrochemical acetoxylation, fluorination, and ADC synthesis. 👉 Register here: Registration
Meet our team at events in November
We appreciate your interest in the latest industry developments. Subscribe to find out first about the latest news and stay tuned for more updates and insights in our future issues.
To learn more about our integrated offering in the development and manufacturing of small molecules and bioconjugates, explore our website.
The convergence of AI route scouting, high-throughput optimization, and dual-payload ADC design reflects a maturing model of agile development. Lonza’s platform approach demonstrates how digital tools can de-risk complexity and support better translational decisions faster and with greater molecular precision. Particularly compelling is the combination of mechanistic precision with digital foresight which is a needed step to derisk innovation while scaling impact. Looking forward to the broader integration of these tools across the development spectrum.